Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting
Unknown statusPhase 3NCT02303847
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in opioid-tolerant patients in the primary care outpatient setting.
Study details
- Official title
- Ultra-low Dose Oral Ketamine for Treatment of Chronic Non-cancer Pain in the Primary Care Setting
- Conditions
- Interventions
- Sponsor
- University of Washington
- Start date
- 2014-11
- Primary completion
- 2015-06
- Sex
- All
- Age range
- from 18 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18 years or older * Routine use of an opioid medication for non-cancer pain for more than six months * A current average daily dose of greater than or equal to 20 mg morphine or equivalent * Current prescription of an as-needed opioid suitable for downward titration during the study period * Ability to provide informed consent Ability to adhere to the study protocol Exclusion Criteria: * Uncontrolled hypertension, cardiac arrhythmia or other known cardiac disease, * elevated intracranial pressure, * severe glaucoma, * schizophrenia, * diagnosed substance use disorder, or * other unstable medical or psychiatric illness or pregnancy.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02303847